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Summary Since prostacyclin (PGI2) is known to have a cytoprotective effect on epithelia, and since cigarette
smoking is associated with an increased risk of bladder cancer, we investigated the possibility that nicotine,
cotinine (the prinicpal metabolite of nicotine) and other components of cigarette smoke inhibit PGI2 secretion
by the urinary bladder.
Using the rat urinary bladder as a model, we found that cigarette smoke extracts, but not nicotine or
cotinine, inhibit in vitro PGI2 synthesis. 2-Naphthylamine, a known bladder carcinogen, was also a potent
inhibitor of PGI2 synthesis by the rat bladder. It is possible that cigarette smoke and 2-napthylamine exert
their carcinogenic effect partly through the inhibition of PGI2 synthesis, resulting in diminished urothelial
cytoprotection.
The mammalian bladder synthesises the prostanoid
prostacyclin (PGI2) in quantities comparable to
vascular tissue (Jeremy et al., 1984a,b). Although a
role for PGI2 in this organ has yet to be defined
(Jeremy et al., 1984a), it is possible that this
prostanoid (and certain other PGs) may play a
cytoprotective role in the bladder, similar to that
documented for the gastrointestinal system
(Konturek et al., 1981a,b; Yik et al., 1982), where
certain prostanoids have even been used
successfully to treat peptic ulceration (Vantrappen
et al., 1983). Evidence supporting the view that PGs
play a cytoprotective role in the urinary bladder is
provided by the finding that local administration of
PGE2 improves symptoms caused by schistosomal
ulcers (El. Gendi et al., 1982) and has also been
used successfully to treat cyclophosphamide-
induced haemorrhagic cystitis (Mohiuddin et al.,
1984). Diminution of local PGI2 synthesis may
therefore reduce the cytoprotective capacity of the
urothelium, rendering it more susceptible to the
actions of carcinogens which may be present in the
urine.
Cigarette smoking is linked epidemiologically
with an increased incidence of bladder cancer,
although the mechanisms involved remain
undefined (Morrison et al., 1984). A major
component of cigarette smoke, nicotine, has been
shown to inhibit PGI2 synthesis in vascular tissue
models (Alster et al., 1983). We have also shown
that cigarette smoke extracts, in vitro, inhibit
vascular PGI2 synthesis (unpublished observations).
We therefore studied the effect of nicotine, cotinine
Correspondence: P. Dandona
Received 30 November 1984; and in revised form 14
February 1985
(the major urinary metabolite of nicotine
((Matsukura et al., 1984)) and cigarette smoke
extracts on in vitro PGI2 synthesis by the rat
urinary bladder. We also studied the effect of 2-
naphthylamine on PGI2 synthesis, since this
substance is a known bladder carcinogen (Schmeltz
& Hoffman, 1977).
Material and methods
Preparation ofcigarette smoke extracts and
condensates
The filter end of a cigarette (middle tar;
approximate tar yield: 21 mg/cigarette; approximate
nicotine yield: 1.3mg/cigarette (Schmeltz &
Hoffman, 1977; Government Chemist, 1974) was
inserted into the end of a 10cm length of plastic
tubing. The other end of the tubing was attached to
tubing in either 10ml Krebs Ringer bicarbonate
buffer (KRB), pH7.4, or in 10mol ethanol,
contained in a flask. This system allowed us to
assess both water-soluble and ethanol-soluble
cigarette smoke components. Vacuum was applied
to the flask through another tube so that the
ignited cigarette was completely consumed (tobacco
portion only) over a 5min period, the smoke
bubbling through the KRB or ethanol in the flask.
The ethanolic extract was evaporated in vacuo
and the remaining condensate was resuspended in
KRB or TRIS assay buffer (ethanolic cigarette
smoke extract - ECSE). Data on ECSE is expressed
as ugml-1 of condensate in buffer.
When cigarette smoke was bubbled though KRB,
data are expressed as cigarette equivalents ml-'
KRB (CS-KRB). Routinely, 1 cigarette was bubbled
through 5ml KRB, yielding 0.2 cigarette equivalents
ml-1 KRB.
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Preparation ofnicotine and cotinine solutions
Nicotine sulfate was obtained from Sigma
Chemicals, Poole, Dorset, UK. Nicotine free base
was obtained from BDH Ltd., Poole, Dorset, UK.
Cotinine (free base) was purchased from Sigma.
The drugs were made up fresh in KRB prior to
each experiment.
Tissue preparation and structure ofexperiments
Male Sprague-Dawley rats (200g) were decapitated,
their bladders excised and placed in chilled KRB.
The bladders were cut longitudinally into two equal
halves and further cut longitudinally into 6 strips
with a scalpel blade on a Teflon block. Each strip
was then cut into 2mm squares and placed in
chilled KRB prior to incubations.
The following experiments were then carried out:
(i) Effect of CS-KRB, ECSE, nicotine and cotinine
on spontaneous PGI2 release by bladder tissue
squares Twenty mg portions of each tissue
preparation, in octuplicate, were placed in ml
ECSE (final concentration: 0-1 g condensate I1-
buffer) and CS-KRB (final concentration: 0-0.4
cigarette equivalents ml-' KRB). Changes in buffer
pH were monitored and adjusted accordingly to
pH 7.4 with dilute HCI or NaOH. Bladder tissue
was then incubated for 60min in a shaking water
bath (37°C). At the end of incubation, the sample
was centrifuged and an aliquot of the supernatant
was collected and diluted with radioimmunoassay
buffer for estimation of 6-oxo-PGF1a (the stable,
spontaneous metabolite of PGI2) concentration,
using a specific radioimmunoassay (see details
below).
Nicotine free base and nicotine sulphate
produced identical effects and therefore the results
have been summated.
Radioimmunoassay of6-oxo-PGF,a Antisera for 6-
oxo-PGF1a assays were purchased from Cappel
Laboratories, West Chester, Pa., USA, and [3H]-6-
oxo-PGFpa (160Cimmol 1) from New England
Nuclear, Boston, Ma., USA, Unlabelled 6-oxo-
PGFpa was a gift from Upjohn Co., Kalamzoo,
Mi., USA. Assays were carried out according to
protocols obtained from Cappel Laboratories
(Jeremy et al., 1984a,c; Mikhailidis et al., 1983).
(ii) Effect of carcinogens on spontaneous release of
PGI2 by bladder tissue The known bladder
carcinogen, 2-napthylamine (Schmeltz & Hoffman,
1977), was studied as in (i) above, Quinoline, N-
alkyl carbazole, hydrazine, and dibenzocarbazole as
tumour initiators or accelerators (Schmeltz &
Hoffman, 1977), were also studied. These chemicals
were purchased from BDH, Poole, Dorset, UK.
(iii) Effect of ECSE, nicotine, cotinine and 2-naph-
tylamine on 14C-arachidonic acid conversion into
6-oxo-PGF1c by rat urinary bladder tissue
Conversion of 14C-arachidonic acid (14C-AA) into
6-oxo-PGFca was carried out as previously des-
cribed (Jeremy et al., 1983, 1985). Briefly, 20mg of
urinary bladder tissue were incubated, in octuplicate,
in 100 ul TRIS-HCl buffer [pH 8.0; containing
ImmolI-t EDTA; 150mmolP1 NaCl and
250nCi 14C-AA (52mCimmol-1), New England
Nuclear, Boston, Ma., USA]. ECSE, nicotine,
cotinine and 2-naphthylamine were dissolved in
TRIS buffer to study dose reponse relationships as
described in (i) above. Following incubation, the
tissue was extracted with x 2 ethanol (Aristar,
BDH, Poole, UK)andpooledsupernatant evaporated
in vacuo. 14C-6-oxo-PGF,a and unchanged 14C-AA
were separated by thin layer chromatography (tlc)
on silica gel precoated plastic plates (Merck
Darmstadt, W. Germany) run in the organic phase
of an ethyl acetate: 2,2,4, trimethylpentane; acetic
acid; water mix (Jeremy et al., 1983, 1985). The
zones corresponding to 6-oxo-PGF1a and AA were
cut and assayed for radioactivity by liquid
scintillation counting and % conversion of 14C-AA
to 14C-6-oxo-PGFpx was calculated (Nadler et al.,
1983; Chechoway et al., 1983).
Statistical analysis and presentation ofdata
Data are presented as median and range (Altman et
al., 1983). Results in control experiments are
compared with those in the presence of agents or
extracts being evaluated using a non-parametric
Mann-Whitney test (two-tailed) (Altman et al., 1983)
Results
(i) Effect ofcigarette smoke (bubbled through Krebs-
Ringer bicarbonate buffer; CS-KRB) on spontaneous
in vitro release of PGI2 (measured as 6-oxo-PGF1L):
Table I CS-KRB was significantly (P<0.01) inhibi-
tory to in vitro PGI2 at 0.05 cigarette equivalents
ml. Higher CS-KRB concentrations produced pro-
gressively more severe inhibition of PGI2 release.
The inhibitory trend of CS-KRB was evident at
0.0125 and 0.025 cigarette equivalents ml-', but
this did not achieve statistical significance.
(ii) Effect of ethanolic cigarette smoke extracts
(ECSE) on spontaneous in vitro PGI2 release
(measured as 6-oxo-PGF1c): Table II Results were
very similar to those described in (i) above. The
inhibitory trend was again evident at concentrations
below those which showed statistical significance.
(iii) The effect ofnicotine and cotinine on spontaneous
in vitro release of PGI2 (measured as 6-oxo-PGF1ax):CIGARETTE SMOKE AND PROSTACYCLIN SYNTHESIS 839
Table I The effect of cigarette smoke (bubbled through Krebs Ringer
bicarbonate buffer; CS-KRB) on spontaneous release of PGI2
(measured as 6-oxo-PGFla) from rat bladder tissue. 6-oxo-PGFpx
(ng20mg tissue 1 60min- ) is expressed as median and (range)
Cigarette equivalents/ml KRB
0 0.0125 0.025 0.05 0.1 0.2 0.4
41 34 27 23a 18b 14b 6b
(26-50) (22-39) (24-33) (18-30) (14-25) (8-20) (3-9)
aP<0.01: 0 vs 0.05.
bp<0.002:0vs0.1,0vs0.2;0vs0.4cigaretteequivalents ml-.
Table II The effect of ethanolic extracts of cigarette
smoke in KRB (ECSE) on spontaneous in vitro release of
PGI2 (measured as 6-oxo-PGF,a) from rat bladder tissue.
6-oxo-PGFpx (ng20mg tissue-' 60min-1) is expressed as
median and (range)
Ethanolic cigarette smoke extract (g1')
I (control) 0.125 0.25 0.5 1.0
45 36 24a 18a 7a
(36-52) (28-44) (20-38) (14-26) (5-8)
aP<0.002: 0 vs 0.25; 0 vs 0.5; 0 vs 1.0gl 1.
Table Ill The effect of nicotine (N) and cotinine (C) on spontaneous in vitro release of PGI2
(measured as 6-oxo-PGF1a) from rat bladder tissue. 6-oxo-PGFpa (ng 20mg tissue-' 60minm1)
is expressed as median and (range)
Nicotine (N) and cotinine (C) concentrations (g-1')
0 0.125 0.25 0.5 1.0
(control) N C N C N C N C
44 40 41 40 40 40 39 45 40
(31-52) (33-47) (27-56) (34-53) (33-56) (37-47) (39-54) (32-51)
All statistical comparisons were not significant.
Table III Up to lgl-' concentrations of both
nicotine and its main metabolite, cotinine, did not
inhibit PGI2 release.
(iv) Effect of ethanolic cigarette smoke extracts
(ECSE) on the conversion of 14C arachidonic acid
(14C-AA) to 6-oxo-PGF1a: Table IV ECSE signifi-
cantly inhibited the conversion of 14C-AA to 6-oxo-
PGF1a at concentrations of 0.25gI-1 and above.
(v) Effect of nicotine and cotinine on the conversion
of 14C-arachidonic acid (14C-AA) to 6-oxo-PGF1a:
Table V Up to 1 g -1' concentrations of both
nicotine and its metabolite, cotinine, did not inhibit
the conversion of '4C-AA to 6-oxo-PGF1cx.
(vi) Effect of 2-naphthylamine on spontaneous PGI2
release (measured as 6-oxo-PGFpx): Table VI 2-
napthylamine significantly inhibited PGI2 release at
concentrations of 1OOugl- and above.
(vii) Effect of quinoline, N-alkyl carbazole, hydrazine
and dibenzocarbazole on spontaneous release ofPGI2
release (measured as 6-oxo-PGF,a) These agents
were without effect at concentrations of up to
lOOmglPt.840 J.Y. JEREMY et al.
Table IV The effect of ethanolic cigarette smoke extract
(ECSE) on the conversion by rat bladder tissue of 14C-
arachidonic acid to 6-oxo-PGF,a. 6-oxo-PGF1a (nCi
20mg tissue-1 90min-1) is expressed as median and
(range)
Ethanolic cigarette smoke extract (g1-)
0 0.125 0.25 0.5 1.0
20 18 16a job 3.Ob
(15-26) (16-20) (12-18) (7-12) (2-6)
aP=0.01: 0 vs 0.25.
bP<0.002: 0 vs 0.5 and 0 vs 1.Og g .
Table V Effect of nicotine (N) and cotinine (C) on the conversion by rat bladder tissue of `4C-
AA to 6-oxo-PGF,a. 6-oxo-PGF,a (nCi 20mg tissue-' 90min-') is expressed as median and
(range)
Nicotine (N) and cotinine (C) concentrations (g1-')
0 0.125 0.25 0.5 1.0
(control) N C N C N C N C
20 20 21 20 20 21 22 19 20
(15-26) (18-24) (14-26) (16-24) (18-22) (14-26) (20-24) (16-26) (14-26)
All statistical comparisons were not significant.
Table VI Effect of 2-naphthylamine on spontaneous PGI2
release (assessed as 6-oxo-PGF,a) from rat bladder tissue. 6-oxo-
PGF,a (ng 20mg tissue-' 60min-1) is expressed as median and
(range)
2-naphthylamine concentration
0 loJgl-V 100 ugl- Jmgl'l lOmgl- 1JOOmglV
41 38 30a 22a 16a 10"
(36-50) (28-52) (27-36) (17-26) (14-20) (6-04)
'P<0.002: 1 vs 100yigl-; 0 vs lmglP'; 0 vs lOmgl-'; 0 vs
lOOmglP'.
Discussion
We have previously demonstrated that the rat and
cat urinary bladder produce PGI2 (Jeremy et al.,
1984a,b). The relative contributions of the bladder
urothelium and muscle layers to local PGI2
production are undefined at present. However, it is
clear that substantial amounts of PGI2 are released
into the lumen of isolated whole rat bladders, in
vitro (Jeremy et al., 1984a). The exact role, if any,
played by this prostanoid and by the smaller
amounts of other prostanoids also synthesised by
the bladder, (thromboxane A2, PGE2) remains to be
defined (Jeremy et al., 1984a). One possible function,
however, is that PGI2 acts as a local cytoprotective
agent in a manner similar to that shown in the
human stomach (Konturek et al., 1981a,b; Yik et al.,
1982). It follows, therefore, that inhibition of local
PGI2 synthesis in the urinary bladder may com-
promise this organ's local defences against infection
or carcinogenesis. Certainly it would appear that
exogenous administration of prostanoids exerts
beneficial healing effects in bladder pathology
(El-Gendi et al., 1982; Mohiuddin et al., 1984).
It is, perhaps, more than coincidence that both
schistosomal bladder ulcers and cyclophosphamide-
induced haemorrhagic cystitis, which were success-
fully treated by exogenous prostanoids (El-GendiCIGARETTE SMOKE AND PROSTACYCLIN SYNTHESIS 841
et al., 1982; Mohiuddin et al., 1984), are risk factors
in the pathogenesis of bladder cancer (Elem &
Burohit, 1983; Fuchs et al., 1981). It is also of
interest that aspirin, which inhibits cyclooxygenase
activity (and therefore prostacyclin synthesis), can
act as a co-carcinogen in certain animal models
(Hasagawa et al., 1984; Chang et al., 1983).
The known association between smoking and an
increased risk of bladder carcinoma (Morrison et
al., 1984) prompted us to investigate whether
cigarette smoke extracts can inhibit PGI2 synthesis
by the bladder. Our findings indicate that cigarette
smoke extracts and condensates are indeed
inhibitors of in vitro PGI2 synthesis by rat bladder
tissue. Since both spontaneous PGI2 release and the
conversion of AA to PGI2 were inhibited by smoke
extracts, it is likely that the action of these
compounds is, at least in part, exerted on the
enzyme steps (cyclo-oxygenase; PGI2 synthetase)
which are beyond phospholipase A2, the enzyme
which releases AA from membrane phospholipids to
make it available for PGI2 synthesis. This
inhibitory action is not likely to be mediated by
nicotine alone, since high concentrations of this
substance did not inhibit PGI2 synthesis. Cotinine,
the main urinary metabolite of nicotine (Matsukura
et al., 1984), also does not appear to exert any
significant effect on in vitro PGI2 synthesis in our
model. The other components of cigarette smoke
evaluated also did not seem to exert any significant
inhibitory action, except for 2-naphthylamine, a
known carcinogen (Schmeltz & Hoffman, 1977;
Purchase et al., 1981) which is present in cigarette
smoke (Schmeltz & Hoffman, 1977). The positive
findings with 2-naphthylamine are also of interest,
since this compound is a recognised initiator of
bladder carcinomas in man and experimental
animal models (Schmeltz & Hoffman, 1977;
Purchase et al., 1981). In addition, 2-naphthylamine
and related compounds are found in the rubber
industry (Checkoway et al., 1981). It is therefore of
interest that in increased incidence of bladder
cancer is associated with those working in this
industry (Checkoway et al., 1981).
The fact that the present study was conducted
using rat bladders rather than human tissues
presents a disadvantage. However, it should be
noted that human tissue obtained from pathological
bladders or at necropsy may not be appropriate
models. Substantial full thickness tissue samples
obtained from healthy volunteers raises obvious
ethical questions. Measurement of urinary 6-oxo-
PGF1o (the spontaneous, stable metabolite of PGI2)
concentrations as in indirect index of PGI2
production by the bladder is also unsatisfactory,
since PGI2 in the urine may also originate from
systemic and renal/ureteric sources (Jeremy et al.,
1984; Nadler et al., 1983; Mikhailidis et al., 1983).
Furthermore, the stability and the rate of
production of PGI2 in organs other than the
bladder may influenced by experimental conditions,
such as smoking (Nadler et al., 1983; Mikhailidis et
al., 1983). Urine contamination from urethral,
seminal or uterine tissue may also cause problems.
Finally, it is clearly unethical to expose humans to
known carcinogens, even in small doses. It would
therefore appear that future work evaluating the
role played by bladder prostanoids will be largely
limited to experimental models, and perhaps to
therapeutic intervention trials in humans. The
concept that prostaglandins act as cytoprotective
barriers which offer some degree of protection from
local carcinogenesis/infection clearly deserves
further exploration.
We thank Pamela Dale for secretarial assistance.
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